Per the relevant Regulation for the Control of Narcotic Drugs and Psychotropic Substances, on August 6, 2019, NMPA, the Ministry of Public Security, and the National Health Commission decided to include oxycodone-containing compound preparations in the management of psychotropic substances. The Announcement reads as follows:

1. Oral solid preparations containing more than 5 mg of oxycodone base per dose unit, barring other narcotic drugs, psychotropic drugs or pharmaceutical precursor chemicals, shall be subject to the management of Class I psychotropic drugs;

2. Oral solid preparations containing no more than 5 mg of oxycodone base per dose unit, barring other narcotic drugs, psychotropic drugs or pharmaceutical precursor chemicals, shall be subject to the management of Class II psychotropic drugs;

3. Compound oral solid preparations of buprenorphine and naloxone shall be subject to the management of Class II psychotropic drugs.

This Announcement shall come into force on September 1, 2019.